.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Sarcoidosis is a complex multisystem granulomatous syndrome that presents significant clinical challenges due to its wide range of manifestations. Emerging research suggests that tofacitinib for sarcoidosis may offer a novel therapeutic avenue. This JAK inhibitor modulates immune responses and reduces the formation of granulomas. Recent findings indicate that tofacitinib works by targeting specific signaling pathways and restoring immune cell equilibrium.
The primary mechanism behind the effectiveness of tofacitinib involves the suppression of the JAK3/STAT5 signaling pathway. Furthermore, the treatment induces pyroptosis, as shown by increased levels of cleaved-Gasdermin D. These actions significantly reduce the inflammatory burden within the granulomatous environment. Consequently, researchers observed a marked reduction in granuloma formation in SodA-induced models.
Tofacitinib therapy effectively re-establishes the balance within the Th1/Th2/Treg/Th17 immune cell profile. Specifically, it restores the functional capacity of regulatory T cells (Tregs) to induce M2 anti-inflammatory macrophage polarization. While the drug increases both M1 and M2-like macrophages, there is a predominant shift toward the M2 phenotype. Moreover, this shift leads to a significant reduction in IL-1β secretion, which further mitigates chronic inflammation.
In addition to macrophage modulation, tofacitinib reduces the proportions of Th17 and Treg cells. Interestingly, the study found that the drug does not significantly affect STAT1 or AKT activation. This selectivity highlights the targeted nature of JAK3/STAT5 inhibition. By promoting M2 polarization and restoring Treg function, tofacitinib provides a comprehensive immunomodulatory effect that addresses the root causes of granuloma persistence.
Tofacitinib reduces granuloma formation by suppressing the JAK3/STAT5 signaling pathway and inducing pyroptosis, which helps clear inflammatory cells and balances the immune response.
Tofacitinib promotes a shift toward M2-like polarization, which is anti-inflammatory. It also restores the ability of Treg cells to facilitate this polarization, reducing the secretion of pro-inflammatory cytokines like IL-1β.
This study specifically highlights the suppression of the JAK3/STAT5 pathway. Notably, tofacitinib did not significantly affect STAT1 activation, suggesting a targeted immunomodulatory role in the context of sarcoidosis.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Sheng T et al. Restoration of Treg function and polarization of M2 macrophages by tofacitinib to alleviate sarcoidosis through the mediation of the JAK3/STAT5 pathway. Mol Immunol. 2026 Jun 07. doi: undefined. PMID: 42251788.
Rotondo C et al. JAK Inhibitors: A New Era for Sarcoidosis Treatment? Frontiers in Medicine. 2023.
Morgenthau AS et al. Tofacitinib for the Treatment of Sarcoidosis. ACR Open Rheumatology. 2020.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study reveals how tofacitinib modulates immune responses in sarcoidosis by inhibiting JAK3/STAT5 and restoring the balance of Treg and M2 macrophages....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
